AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12919340 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiepileptic treatments
Number of subjects: 0
Study 12919340 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient preference
Number of subjects: 0
Study 10675381 — intervention group
Group type: EXPERIMENTAL
Intervention: ATP treatment (10 intravenous 30-hour infusions at 2- to 4-week intervals)
Number of subjects: 58
Study 9308747 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin therapy
Number of subjects: 106
Study 9308747 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 8121306 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine (ARG)
Number of subjects: 14
Study 8121306 — intervention group
Group type: COMPARATOR
Intervention: Lipid-heparin infusion (Control)
Number of subjects: 14
Study 8121306 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH + Arginine (ARG)
Number of subjects: 14
Study 8121306 — intervention group
Group type: COMPARATOR
Intervention: Lipid-heparin infusion (Control) + Arginine (ARG)
Number of subjects: 14
Study 2518866 — intervention group
Group type: EXPERIMENTAL
Intervention: 50-micrograms SMS 201-995
Number of subjects: 8
Study 2518866 — intervention group
Group type: EXPERIMENTAL
Intervention: 100-micrograms SMS 201-995
Number of subjects: 8
Study 2518866 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 869026 — intervention group
Group type: EXPERIMENTAL
Intervention: Unlimited alcohol and/or cigarettes during the second week
Number of subjects: 40
Study 869026 — intervention group
Group type: COMPARATOR
Intervention: Abstinence from alcohol and cigarettes during the first week
Number of subjects: 40
Study 869026 — intervention group
Group type: EXPERIMENTAL
Intervention: Measures of affect (hostility/aggression)
Number of subjects: 40
Study 31843372 — intervention group
Group type: EXPERIMENTAL
Intervention: MFCLs with +2.0 D (Add2)
Number of subjects: 24
Study 31843372 — intervention group
Group type: EXPERIMENTAL
Intervention: MFCLs with +4.0 D (Add4)
Number of subjects: 24
Study 31843372 — intervention group
Group type: COMPARATOR
Intervention: Single vision lenses (SVCL; Add0)
Number of subjects: 24
Study 31843372 — intervention group
Group type: EXPERIMENTAL
Intervention: MFCLs with +2.0 D (Add2) and +4.0 D (Add4)
Number of subjects: 24
Study 31421094 — intervention group
Group type: EXPERIMENTAL
Intervention: Autotitrating CPAP for OSA for 3 months
Number of subjects: 79
Study 27615793 — intervention group
Group type: EXPERIMENTAL
Intervention: Active bilateral prefrontal rTMS
Number of subjects: 24
Study 27615793 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 24
Study 26125769 — intervention group
Group type: EXPERIMENTAL
Intervention: emergency PCI + rhBNP early treatment (Group B)
Number of subjects: 90
Study 26125769 — intervention group
Group type: EXPERIMENTAL
Intervention: emergency PCI + late rhBNP treatment (Group C)
Number of subjects: 90
Study 26125769 — intervention group
Group type: COMPARATOR
Intervention: emergency PCI (Group A)
Number of subjects: 90
Study 24299712 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus CGMCC1.3724 (LPR) supplementation (1.6 × 10(8) colony-forming units of LPR/capsule, 2 capsules per day)
Number of subjects: 0
Study 24299712 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24299712 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus CGMCC1.3724 (LPR) supplementation
Number of subjects: 0
Study 22990514 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive outpatient therapy including mechanical lymph drainage using the RAGodoy® apparatus for 6 to 8 hours daily, Godoy & Godoy cervical stimulation technique for 20 minutes per day, and manual lymph drainage for one hour.
Number of subjects: 8
Study 19174453 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary lymph node dissection (ALND arm)
Number of subjects: 225
Study 19174453 — intervention group
Group type: COMPARATOR
Intervention: Sentinel lymph node biopsy (SLNB arm)
Number of subjects: 225
Study 17443402 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory focus
Number of subjects: 68
Study 17443402 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction
Number of subjects: 68
Study 17443402 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppression
Number of subjects: 68
Study 17443402 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 68
Study 15082123 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg/day
Number of subjects: 238
Study 15082123 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 300 mg/day
Number of subjects: 238
Study 15082123 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 238
Study 11334123 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (Cys-LT1 antagonist)
Number of subjects: 1500
Study 9127642 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokine expression measured via semi-quantitative RT-PCR for IFN gamma, IL-1 beta, IL-4, and IL-6
Number of subjects: 0
Study 1541492 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic splinting materials (water-activated polyurethanes, thermoplastic)
Number of subjects: 203
Study 1541492 — intervention group
Group type: COMPARATOR
Intervention: Plaster-of-Paris
Number of subjects: 203
Study 2421622 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlormadinone acetate (CMA) therapy for 1 week
Number of subjects: 12
Study 2421622 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlormadinone acetate (CMA) therapy
Number of subjects: 12
Study 30411596 — intervention group
Group type: EXPERIMENTAL
Intervention: Soccer training (4 extra sessions per week)
Number of subjects: 56
Study 30411596 — intervention group
Group type: COMPARATOR
Intervention: Control group (physical fitness sessions at school)
Number of subjects: 56
Study 29411446 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT) during hospitalisation
Number of subjects: 600
Study 29411446 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT) post-discharge
Number of subjects: 600
Study 29411446 — intervention group
Group type: EXPERIMENTAL
Intervention: NRT use during hospitalisation for heavy smokers
Number of subjects: 600
Study 29411446 — intervention group
Group type: EXPERIMENTAL
Intervention: NRT use post-discharge for heavy smokers
Number of subjects: 600
Study 29411446 — intervention group
Group type: EXPERIMENTAL
Intervention: NRT use during hospitalisation for those using six or more medications
Number of subjects: 600
Study 29411446 — intervention group
Group type: EXPERIMENTAL
Intervention: NRT use post-discharge for patients admitted for respiratory or cardiac problems
Number of subjects: 600
Study 29411446 — intervention group
Group type: EXPERIMENTAL
Intervention: NRT use during hospitalisation when offered free of cost
Number of subjects: 600
Study 29411446 — intervention group
Group type: EXPERIMENTAL
Intervention: NRT use prediction by nicotine dependence
Number of subjects: 600
Study 29411446 — intervention group
Group type: EXPERIMENTAL
Intervention: NRT use prediction by interest in using NRT
Number of subjects: 600
Study 27457914 — intervention group
Group type: EXPERIMENTAL
Intervention: Inertial Training (T0 group, 19.4 kg flywheel)
Number of subjects: 58
Study 27457914 — intervention group
Group type: EXPERIMENTAL
Intervention: Inertial Training (T10 group, 29.4 kg flywheel)
Number of subjects: 58
Study 27457914 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 58
Study 24723432 — intervention group
Group type: EXPERIMENTAL
Intervention: venlafaxine Extended‐Release (XR) treatment
Number of subjects: 156
Study 22178393 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg orally administered hydrocortisone
Number of subjects: 10
Study 22178393 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 10
Study 20334583 — intervention group
Group type: EXPERIMENTAL
Intervention: NuvaRing (various regimens: 21/7, 42/7, 84/7, 357/7)
Number of subjects: 109
Study 20334583 — intervention group
Group type: EXPERIMENTAL
Intervention: NuvaRing (various regimens)
Number of subjects: 109
Study 20334583 — intervention group
Group type: EXPERIMENTAL
Intervention: NuvaRing (longer regimens)
Number of subjects: 109
Study 20334583 — intervention group
Group type: COMPARATOR
Intervention: Control group (no contraception)
Number of subjects: 109
Study 17363530 — intervention group
Group type: EXPERIMENTAL
Intervention: Arsenic trioxide (0.125 or 0.250 mg/kg), bortezomib (0.7, 1.0, or 1.3 mg/m(2)), ascorbic acid (1 g) i.v. on days 1, 4, 8, and 11 of a 21-day cycle for a maximum of eight cycles.
Number of subjects: 22
Study 17363530 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib (0.7 mg/m(2))
Number of subjects: 22
Study 17363530 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib (1.0 or 1.3 mg/m(2))
Number of subjects: 22
Study 15784480 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum 299v (ProViva) in addition to conventional therapy (treatment group, n = 52)
Number of subjects: 103
Study 15784480 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy alone (control group, n = 51)
Number of subjects: 103
Study 11994835 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 91
Study 9862242 — intervention group
Group type: EXPERIMENTAL
Intervention: Acidification of urine pH, low urinary flow (Regimen A)
Number of subjects: 12
Study 9862242 — intervention group
Group type: EXPERIMENTAL
Intervention: Acidification of urine pH, high urinary flow (Regimen B)
Number of subjects: 12
Study 9862242 — intervention group
Group type: COMPARATOR
Intervention: Alkalinization of urine pH, low urinary flow (Regimen C)
Number of subjects: 12
Study 9862242 — intervention group
Group type: COMPARATOR
Intervention: Alkalinization of urine pH, high urinary flow (Regimen D)
Number of subjects: 12
Study 9862242 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimens A and B (acidic urine pH)
Number of subjects: 12
Study 7615313 — intervention group
Group type: EXPERIMENTAL
Intervention: MkII implant
Number of subjects: 103
Study 7615313 — intervention group
Group type: COMPARATOR
Intervention: Standard Brånemark System implant
Number of subjects: 103
Study 2262234 — intervention group
Group type: EXPERIMENTAL
Intervention: MPA-B (methyl prednisolone acetate with bupivacaine)
Number of subjects: 56
Study 2262234 — intervention group
Group type: COMPARATOR
Intervention: MPA-L (methyl prednisolone acetate with lidocaine)
Number of subjects: 56
Study 7392402 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training for one year, including therapeutical physical exercises, dosaged running, elements of sport games, and training on a bicycle ergometer
Number of subjects: 75
Study 7392402 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 75
Study 31633865 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg controlled-release oral morphine
Number of subjects: 60
Study 31633865 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 30001503 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity resistance training (HRT)
Number of subjects: 0
Study 30001503 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training with blood flow restriction (RT-BFR)
Number of subjects: 0
Study 30001503 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 28566024 — intervention group
Group type: EXPERIMENTAL
Intervention: MePrEPA (four-week group psychoeducational intervention)
Number of subjects: 172
Study 28566024 — intervention group
Group type: COMPARATOR
Intervention: Parent-support control group
Number of subjects: 172
Study 26558994 — intervention group
Group type: EXPERIMENTAL
Intervention: Single CT scan assessment of bone mineral density, vascular calcification and fat mass
Number of subjects: 64
Study 26558994 — intervention group
Group type: EXPERIMENTAL
Intervention: Single CT scan assessment of body composition
Number of subjects: 64
Study 26558994 — intervention group
Group type: EXPERIMENTAL
Intervention: QCT analysis
Number of subjects: 64
Study 26558994 — intervention group
Group type: EXPERIMENTAL
Intervention: DXA analysis
Number of subjects: 64
Study 23180154 — intervention group
Group type: EXPERIMENTAL
Intervention: α‐Lipoic acid (1,200 mg d(‐1) for 10 days)
Number of subjects: 16
Study 21506207 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem Solving Education (PSE)
Number of subjects: 93
Study 21506207 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 93
Study 18793232 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscular counterpulsation (MCP) treatment for 30 minutes daily for the first eight postoperative days in addition to standard therapy.
Number of subjects: 50
Study 18793232 — intervention group
Group type: COMPARATOR
Intervention: Standard postoperative treatment without counterpulsation (control group).
Number of subjects: 50
Study 17382730 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine plus boosters
Number of subjects: 75
Study 17382730 — intervention group
Group type: COMPARATOR
Intervention: Placebo only
Number of subjects: 75
Study 15042664 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor size, lymph node status, and tumor grade
Number of subjects: 0
Study 15042664 — intervention group
Group type: EXPERIMENTAL
Intervention: Cox regression model with time‐varying coefficients
Number of subjects: 0
Study 15042664 — intervention group
Group type: EXPERIMENTAL
Intervention: Frailty models
Number of subjects: 0
Study 11573587 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 5 mg ml(-1) with glucose 8 mg ml(-1)
Number of subjects: 40
Study 11573587 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 5 mg ml(-1) with glucose 80 mg ml(-1)
Number of subjects: 40
Study 9784073 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (300 mg/70 kg)
Number of subjects: 0
Study 9784073 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7821012 — intervention group
Group type: EXPERIMENTAL
Intervention: Barrier cream
Number of subjects: 3
Study 7821012 — intervention group
Group type: EXPERIMENTAL
Intervention: Afterwork emollient cream
Number of subjects: 3
Study 7821012 — intervention group
Group type: COMPARATOR
Intervention: No cream (controls)
Number of subjects: 3
Study 3392230 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol (200 mg)
Number of subjects: 40
Study 3392230 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 31563660 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate (20 g/day for 1 week, then 5 g/day for 7 weeks)
Number of subjects: 29
Study 31537373 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin multimineral supplement
Number of subjects: 3983
Study 31537373 — intervention group
Group type: COMPARATOR
Intervention: Iron and folate
Number of subjects: 3983
Study 31537373 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-trimoxazole
Number of subjects: 3983
Study 31537373 — intervention group
Group type: COMPARATOR
Intervention: No co-trimoxazole
Number of subjects: 3983
Study 28130378 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous treatment with the NOAC apixaban
Number of subjects: 650
Study 28130378 — intervention group
Group type: COMPARATOR
Intervention: Vitamin K antagonist (VKA) therapy
Number of subjects: 650
Study 26289478 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic (IK) training
Number of subjects: 47
Study 26289478 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Constant External Resistance (DCER) training
Number of subjects: 47
Study 26289478 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 47
Study 24448329 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulfate 220 mg daily
Number of subjects: 120
Study 24448329 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 20234136 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mg betamethasone in a single dose (group 2)
Number of subjects: 100
Study 20234136 — intervention group
Group type: COMPARATOR
Intervention: Control group (group 1, no betamethasone)
Number of subjects: 100
Study 18359663 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-IFN alpha-2b treatment
Number of subjects: 123
Study 16091926 — intervention group
Group type: EXPERIMENTAL
Intervention: Microperimeter 1 (MP‐1)
Number of subjects: 31
Study 16091926 — intervention group
Group type: COMPARATOR
Intervention: Scanning Laser Ophthalmoscope (SLO)
Number of subjects: 31
Study 16091926 — intervention group
Group type: COMPARATOR
Intervention: Comparison of MP‐1 and SLO
Number of subjects: 31
Study 12823591 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine (150 mg/day) for 104 weeks
Number of subjects: 31
Study 12823591 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine (150 mg/day) for 104 weeks with or without 4 months of interferon (IFN) combination
Number of subjects: 31
Study 12823591 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro transfection studies
Number of subjects: 31
Study 10607275 — intervention group
Group type: EXPERIMENTAL
Intervention: Student-led PBL groups
Number of subjects: 127
Study 10607275 — intervention group
Group type: COMPARATOR
Intervention: Faculty-led PBL groups
Number of subjects: 127
Study 9010561 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific immunotherapy with modified phleum pratense allergenic extracts
Number of subjects: 10
Study 9010561 — intervention group
Group type: COMPARATOR
Intervention: Control group (not treated with specific IT, only with drugs)
Number of subjects: 10
Study 1379739 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycosaminoglycan polysulfate (600 LRU daily for 24 weeks)
Number of subjects: 156
Study 1379739 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study 6360832 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium-vitamin-D-combination (single dose ampoules for peroral application)
Number of subjects: 20
Study 6360832 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31782265 — intervention group
Group type: EXPERIMENTAL
Intervention: Resonance Frequency (RF) breathing
Number of subjects: 10
Study 31782265 — intervention group
Group type: EXPERIMENTAL
Intervention: RF + 1 breaths per minute
Number of subjects: 10
Study 31782265 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous Breathing (SB)
Number of subjects: 10
Study 29989855 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated nodal infradiaphragmatic disease
Number of subjects: 223
Study 29989855 — intervention group
Group type: COMPARATOR
Intervention: Supradiaphragmatic disease
Number of subjects: 223
Study 29989855 — intervention group
Group type: EXPERIMENTAL
Intervention: Infradiaphragmatic HL
Number of subjects: 223
Study 29989855 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive chemotherapy (ABVD and BEACOPPescalated)
Number of subjects: 223
Study 26854042 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile-bearing total knee arthroplasty (MB)
Number of subjects: 93
Study 26854042 — intervention group
Group type: COMPARATOR
Intervention: Fixed-bearing total knee arthroplasty (FB)
Number of subjects: 93
Study 24444116 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (4 grams over 15 minutes, followed by 16 grams over 24 hours)
Number of subjects: 1700
Study 24444116 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo (4 grams over 15 minutes, followed by matched placebo over 24 hours)
Number of subjects: 1700
Study 24444116 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Number of subjects: 1700
Study 24444116 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 1700
Study 21919555 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (ASA)
Number of subjects: 0
Study 21919555 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (CLP)
Number of subjects: 0
Study 21919555 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19423614 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram 20 mg daily for 7-10 days
Number of subjects: 23
Study 19423614 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsule daily for 7-10 days
Number of subjects: 23
Study 17637587 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral lorazepam 0.035 mg/kg (Group A)
Number of subjects: 60
Study 17637587 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral lorazepam 0.035 mg/kg (Group C)
Number of subjects: 60
Study 17637587 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral lorazepam 0.035 mg/kg (Group D)
Number of subjects: 60
Study 17637587 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group B)
Number of subjects: 60
Study 16085789 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (2.5 mg-10 mg/day; mean: 5.2 mg/day)
Number of subjects: 204
Study 16085789 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (0.5 mg-2 mg/day; mean: 1.0 mg/day)
Number of subjects: 204
Study 16085789 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study 12376586 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion SR 300 mg/d for 26 weeks, increased to 400 mg/d if <5% weight loss at week 12
Number of subjects: 384
Study 12376586 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion SR
Number of subjects: 384
Study 12376586 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 384
Study 10503817 — intervention group
Group type: EXPERIMENTAL
Intervention: OAC (omeprazole-amoxycillin-clarithromycin)
Number of subjects: 805
Study 10503817 — intervention group
Group type: EXPERIMENTAL
Intervention: OMC (omeprazole-metronidazole-clarithromycin)
Number of subjects: 805
Study 10503817 — intervention group
Group type: COMPARATOR
Intervention: AC (amoxycillin-clarithromycin)
Number of subjects: 805
Study 10503817 — intervention group
Group type: COMPARATOR
Intervention: MC (metronidazole-clarithromycin)
Number of subjects: 805
Study 10503817 — intervention group
Group type: EXPERIMENTAL
Intervention: OAC and OMC
Number of subjects: 805
Study 10503817 — intervention group
Group type: EXPERIMENTAL
Intervention: All regimens
Number of subjects: 805
Study 7850924 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea (HU) administered via intravenous infusion or oral administration
Number of subjects: 0
Study 2262487 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic CNS therapy (St. Jude regimen)
Number of subjects: 94